227 related articles for article (PubMed ID: 27766393)
21. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
22. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
24. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
25. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease.
Greinix HT; Worel N; Knobler R
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1747-8; author reply 1749. PubMed ID: 20601039
[No Abstract] [Full Text] [Related]
26. MPO is a potential biomarker of acute graft-versus-host disease.
Ge B; Ye H
Biomark Med; 2013 Jun; 7(3):391-3. PubMed ID: 23734800
[No Abstract] [Full Text] [Related]
27. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers.
Wolff D; Ayuk F; Elmaagacli A; Bertz H; Lawitschka A; Schleuning M; Meyer RG; Gerbitz A; Hilgendorf I; Hildebrandt GC; Edinger M; Klein S; Halter J; Mousset S; Holler E; Greinix HT
Biol Blood Marrow Transplant; 2013 May; 19(5):767-76. PubMed ID: 23376495
[TBL] [Abstract][Full Text] [Related]
28. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.
Nishikawa S; Okamura A; Yamamori M; Minagawa K; Kawamori Y; Kawano Y; Kawano H; Ono K; Katayama Y; Shimoyama M; Matsui T
Transplant Proc; 2009 Nov; 41(9):3873-6. PubMed ID: 19917404
[TBL] [Abstract][Full Text] [Related]
29. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.
Dietrich S; Okun JG; Schmidt K; Falk CS; Wagner AH; Karamustafa S; Radujkovic A; Hegenbart U; Ho AD; Dreger P; Luft T
Haematologica; 2014 Mar; 99(3):541-7. PubMed ID: 24142995
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stromal cells for steroid-refractory acute GvHD.
Fernández-Maqueda C; Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Sánchez R; Bueno JL; Bautista G; De Liglesia A; Gutiérrez Y; García-Berciano M; Forés R; Royuela A; Fernández MN; Duarte RF; Cabrera-Marín JR
Bone Marrow Transplant; 2017 Nov; 52(11):1577-1579. PubMed ID: 28783146
[No Abstract] [Full Text] [Related]
31. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Remberger M
Haematologica; 2005 Jul; 90(7):870. PubMed ID: 15996922
[No Abstract] [Full Text] [Related]
33. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
35. [Hypofibrinogenemia associated with steroid therapy for the patients who developed GVHD after allogeneic stem cell transplantation].
Moroga Y; Takata H; Yoshida N; Nagamatsu K; Nashimoto Y; Saburi M; Takano K; Ikebe T; Kohno K; Ogata M; Shirao K
Rinsho Ketsueki; 2015 Jul; 56(7):883-8. PubMed ID: 26251153
[TBL] [Abstract][Full Text] [Related]
36. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.
Kuwatsuka Y; Atsuta Y; Hirakawa A; Uchida N; Inamoto Y; Najima Y; Ikegame K; Eto T; Ozawa Y; Ichinohe T; Inoue M; Kimura T; Okamoto S; Miyamura K; Fukuda T
Int J Hematol; 2020 Dec; 112(6):841-850. PubMed ID: 32875487
[TBL] [Abstract][Full Text] [Related]
37. High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease.
Blanchard SK; Sullivan KM; Hooten JN; Holcomb ZE; Rowe Nichols K; Selim MA; Rao CL; Hall RP; Chao NJ; Cardones AR
Br J Dermatol; 2019 Oct; 181(4):869-871. PubMed ID: 31017659
[No Abstract] [Full Text] [Related]
38. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
39. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab.
Unal S; Sag E; Kuskonmaz B; Kesici S; Bayrakci B; Ayvaz DC; Tezcan I; Yalnızoglu D; Uckan D
Pediatr Blood Cancer; 2014 May; 61(5):928-30. PubMed ID: 24307660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
